--- title: "Hong Kong stock movement: HAIXI PHARMA's stock price fluctuates sharply, can the incentive plan and profit expectations stabilize market confidence?" type: "News" locale: "en" url: "https://longbridge.com/en/news/284705898.md" description: "HAIXI PHARMA rose by 13.47%; CSPC Pharmaceutical Group fell by 0.60%, with a transaction volume of HKD 488 million; China Biologic Products fell by 0.92%, with a transaction volume of HKD 156 million; Hansoh Pharmaceutical rose by 0.27%, with a transaction volume of HKD 153 million; Heng Rui Medicine fell by 2.10%, with a market value of HKD 432.4 billion" datetime: "2026-04-30T06:17:01.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284705898.md) - [en](https://longbridge.com/en/news/284705898.md) - [zh-HK](https://longbridge.com/zh-HK/news/284705898.md) --- # Hong Kong stock movement: HAIXI PHARMA's stock price fluctuates sharply, can the incentive plan and profit expectations stabilize market confidence? **Hong Kong Stock Movement** HAIXI PHARMA rose by 13.47%. Based on recent key news: 1. On April 28, HAIXI PHARMA's stock price experienced significant fluctuations, rising 7% to a historical high of HKD 302.4 in the morning session, then falling 21.87% to HKD 219.4. This volatility is related to the rapid increase in the company's stock price since late March, during which the price doubled. The unlocking of cornerstone investors' shares may have exacerbated market fluctuations. Source: Zhitong Finance 2. On April 29, HAIXI PHARMA's board of directors resolved to adopt an H-share incentive plan aimed at motivating core employees and promoting the company's sustainable and healthy development. This move may enhance market confidence in the company's future development. Source: Zhitong Finance 3. Recently, Shenwan Hongyuan's research report pointed out that HAIXI PHARMA has been profitable through its generic drug business for five consecutive years, with operating revenue and net profit expected to grow by 25% and 30% year-on-year in 2025, respectively. The company's progress in innovative drug research and development is smooth, which may elevate market expectations. Source: Zhitong Finance, significant progress in innovative drug R&D in the pharmaceutical industry. **Stocks with High Trading Volume in the Industry** CSPC Pharmaceutical Group fell by 0.60%. Based on recent key news: 1. On April 30, CSPC Pharmaceutical Group's self-developed liposomal amphotericin B injection received approval for listing in the EU, achieving a "zero breakthrough" for Chinese liposomal formulations in Europe, enhancing the company's competitiveness in the international market. 2. On April 29, CSPC Pharmaceutical Group's investigational new drug application for the antibody-drug conjugate SYS6051 was approved by the U.S. FDA, allowing clinical trials to be conducted in the U.S., further strengthening the company's R&D capabilities in the oncology field. 3. On April 24, Huatai-PB Fund Management Co., Ltd. increased its holdings in CSPC Pharmaceutical Group by 7.282 million shares, demonstrating market confidence in the company's future development. The competition in innovative drug R&D in the pharmaceutical industry is fierce, with high market volatility risks. China Biologic Products Holdings fell by 0.92%. Based on recent key news: 1. On April 28, China Biologic Products announced the appointment of Dr. Kang Xiaoyan as Chief Medical Officer, with Dr. Liu Meng and Dr. Liu Rongjun responsible for clinical development in chronic diseases and autoimmune diseases, respectively. These personnel changes aim to strengthen the company's capabilities in innovative drug R&D and promote its international strategy. 2. On April 29, the company spent HKD 10.0088 million to repurchase 1.83 million shares, showing confidence in the company's future development. Share repurchase actions are typically seen as support for the stock price and may have a positive impact on market sentiment. 3. On April 29, Vice Chairman Zheng Xiangling increased her holdings by 1 million shares, indicating executives' confidence in the company's prospects. Such increases in holdings are generally viewed as support for the company's future development and may positively affect the stock price. The pharmaceutical industry is accelerating innovation, with significant capital inflows. Hansoh Pharmaceutical rose by 0.27%. Based on recent key news: 1. On April 30, Hansoh Pharmaceutical's self-developed B7-H3 targeted antibody drug HS-20093 was approved by the National Medical Products Administration for inclusion as a breakthrough therapy, indicated for advanced castration-resistant prostate cancer This approval has enhanced market confidence in the company's R&D capabilities, driving up the stock price. 2. On April 29, Hansoh Pharmaceutical announced the transfer of exclusive licensing rights for KiOmedine One to Heng Rui Medicine, with a transaction amount of 131 million RMB. This move is seen as a sign of the company's strategic shift towards other therapeutic areas, and the market reacted positively. 3. On April 28, Hansoh Pharmaceutical updated its final dividend announcement for the fiscal year 2025, maintaining the dividend at HKD 0.2 per share. The stable dividend policy provides confidence to investors, supporting the rise in stock price. The pharmaceutical industry's R&D innovation is accelerating, attracting high market attention. **Stocks Ranked Among the Top in Industry Market Value** Heng Rui Medicine fell by 2.10%. Based on recent key news: 1. On April 28, Heng Rui Medicine signed a strategic cooperation agreement with Sun Yat-sen University to promote the collaborative development of pharmaceutical innovation and medical education, aiding the high-quality development of the biopharmaceutical industry. This move demonstrates the company's proactive layout in the innovation field but failed to immediately boost the stock price. 2. On April 27, Heng Rui Medicine reached a global development agreement for GLP-1 products with Kailera, with initial payments and potential milestone payments totaling up to USD 6 billion. Although this cooperation shows the company's potential for international development, market concerns about short-term returns may lead to a decline in stock price. 3. On April 29, Heng Rui Medicine obtained exclusive licensing for KiOmedine One from Hansoh Pharmaceutical, enhancing its product line in the orthopedic treatment field. However, the market remains cautious about the short-term financial impact of this transaction, failing to boost the stock price. The Hong Kong stock pharmaceutical sector is experiencing fluctuations, with weak liquidity ### Related Stocks - [02637.HK](https://longbridge.com/en/quote/02637.HK.md) - [01093.HK](https://longbridge.com/en/quote/01093.HK.md) - [01177.HK](https://longbridge.com/en/quote/01177.HK.md) - [03692.HK](https://longbridge.com/en/quote/03692.HK.md) - [01276.HK](https://longbridge.com/en/quote/01276.HK.md) ## Related News & Research - [Antengene Names New Chief Scientific Officer to Drive Next-Generation R&D Pipeline](https://longbridge.com/en/news/286980494.md) - [Coffee Prices Pressured by an Improved Brazil Coffee Crop Outlook](https://longbridge.com/en/news/286795965.md) - [Market Chatter: NATO Discussing Hormuz Deployment to Help Guide Ships](https://longbridge.com/en/news/286930669.md) - [ZAWYA: KIB Group, represented by KIB Invest, acts as Joint Lead Manager in landmark $700mln Sukuk issuance by First Abu Dhabi Bank](https://longbridge.com/en/news/287054139.md) - [Eating Watermelon May Help Support Heart Health, Studies Suggest](https://longbridge.com/en/news/286806415.md)